Literature DB >> 22951321

Inflammation and apoptosis in malignant transformation of sinonasal inverted papilloma: the role of the bridge molecules, cyclooxygenase-2, and nuclear factor κB.

Bit-Na Yoon1, Kyong-Myong Chon, Sung-Lyong Hong, Jung-Hoon Lee, Jee-Yeon Kim, Kyu-Sup Cho, Hwan-Jung Roh.   

Abstract

PURPOSE: This study examined the early events in the neoplastic progression of the sinonasal inverted papilloma to squamous cell carcinoma from the viewpoint of chronic inflammation and apoptosis.
MATERIALS AND METHODS: In total, 118 archival slides stained with hematoxylin and eosin from 45 patients were graded according to histopathology (grades I-IV). Their representative portions were transferred to a tissue microarray, sections of which were stained immunohistochemically for cyclooxygenase-2, p53, bax, bcl-2, and nuclear factor κB.
RESULTS: Cyclooxygenase-2 expression was positively correlated with histopathologic grade, with higher expression in advanced grades. p53s were detected in all cores from advanced grades (III, IV), but not in early grades (I, II). The expressions of nuclear factor κB, bax, and bcl-2 were not correlated with the grade.
CONCLUSIONS: A p53 mutation seems be a critical event for the malignant transformation of the sinonasal inverted papilloma. Cyclooxygenase-2-mediated inflammatory signals, activated as a consequence of the p53 mutation, may contribute to promoting the proliferation of the advanced sinonasal inverted papilloma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951321     DOI: 10.1016/j.amjoto.2012.07.008

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  8 in total

1.  Advances in recurrence and malignant transformation of sinonasal inverted papillomas.

Authors:  Qingjia Sun; Lifeng An; Jun Zheng; Dongdong Zhu
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

Review 2.  Malignant transformation of sinonasal inverted papilloma and related genetic alterations: a systematic review.

Authors:  M Re; F M Gioacchini; A Bajraktari; M Tomasetti; S Kaleci; C Rubini; A Bertini; G Magliulo; E Pasquini
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-21       Impact factor: 2.503

3.  Potential malignant transformation in the gastric mucosa of immunodeficient mice with persistent Mycoplasma penetrans infection.

Authors:  Shuyan Cao; Dandan Shen; Yadong Wang; Linxi Li; Liping Zhou; Yuxue Wang
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

4.  Clinical effects of p53 overexpression in squamous cell carcinoma of the sinonasal tract: A systematic meta-analysis with PRISMA guidelines.

Authors:  Xiaowei Wang; Wei Lv; Fang Qi; Zhiqiang Gao; Hua Yang; Weiqing Wang; Yali Gao
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

5.  Clinical evidence based review and systematic scientific review in the identification of malignant transformation of inverted papilloma.

Authors:  Cai Long; Basel Jabarin; Alexandra Harvey; Jennifer Ham; Amin Javer; Arif Janjua; Andrew Thamboo
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-04-30

6.  COX-2 Overexpression in Schneiderian Papillomas.

Authors:  Jeffrey D Suh; Kevin Hur; Elisabeth H Ference; David D Lam; Andrew Fong; Adrian J Correa; Bozena Wrobel
Journal:  Allergy Rhinol (Providence)       Date:  2020-12-08

7.  Human papillomavirus infection and immunohistochemical expression of cell cycle proteins pRb, p53, and p16(INK4a) in sinonasal diseases.

Authors:  Yukashi Yamashita; Masahiro Hasegawa; Zeyi Deng; Hiroyuki Maeda; Shunsuke Kondo; Asanori Kyuna; Sen Matayoshi; Shinya Agena; Takayuki Uehara; Hideaki Kouzaki; Takeshi Shimizu; Taro Ikegami; Akira Ganaha; Mikio Suzuki
Journal:  Infect Agent Cancer       Date:  2015-08-04       Impact factor: 2.965

Review 8.  Etiology of sinonasal inverted papilloma: A narrative review.

Authors:  Ming-Jie Wang; Julia E Noel
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2016-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.